The Indian pharmaceutical market flattened after the pandemic led to a massive upsurge in demand for drugs. The industry saw a rise in sales during the Covid spike but that settled down as the number of coronavirus cases came down, except for Q1FY2022, where the second Covid wave was dominant. This resulted in a dip in the top line of pharma companies in the successive quarters.
